drugset / Trial / NCT04167917
NTX-301 in MDS/AML
NaSingle-groupOpen-labelTreatment
Summary
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Timeline
- Start
- 2021-01-06
- Primary completion
- 2025-04-24
- Completion
- 2025-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NTX-301 | Other / unclassified | — | Oral |